Verici Dx plc (LON:VRCI – Get Free Report)’s stock price reached a new 52-week low during trading on Monday . The company traded as low as GBX 5 ($0.07) and last traded at GBX 5.04 ($0.07), with a volume of 948847 shares traded. The stock had previously closed at GBX 5.70 ($0.07).
Verici Dx Stock Performance
The firm has a 50-day simple moving average of GBX 6.64 and a two-hundred day simple moving average of GBX 7.15. The company has a market capitalization of £10.61 million, a price-to-earnings ratio of -218.75 and a beta of 1.59. The company has a debt-to-equity ratio of 4.65, a quick ratio of 8.49 and a current ratio of 4.54.
Verici Dx Company Profile
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Further Reading
- Five stocks we like better than Verici Dx
- What Are Dividend Champions? How to Invest in the Champions
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Where Do I Find 52-Week Highs and Lows?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
